Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Study to Investigate the Relative Bioavailability of Binimetinib 3 x15 mg and 45 mg Tablets in Healthy Participants

The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration. For the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation, the recommended dosing regimen is 45 mg twice daily (bis in die, BID). No food effect with the commercial formulation of 15 mg was demonstrated.

In order to reduce the patient's burden, a new strength tablet containing 45 mg of binimetinib as active ingredient is being developed. As a result, the number of tablets to be taken by the patients will be reduced from 6 tablets (6 x 15 mg) to 2 tablets (2 x 45 mg) per day. The evaluation of the relative bioavailability of the 45 mg tablet in comparison to three 15 mg tablets intake is therefore required.

Study Overview

• Status: Active, not recruiting
• Conditions: Melanoma; Metastatic Melanoma; Unresectable Melanoma; BRAF V600 Mutation
• Intervention / Treatment: Drug: Binimetinib Oral Tablet

Detailed Description

The R formulation is the currently commercially available tablet containing 15 mg of binimetinib as active substance, administered as three tablets for a total of 45 mg binimetinib. The T formulation is the tablet containing 45 mg of binimetinib as active substance in one tablet. Participants will be randomized to one of 2 treatment sequences (RT or TR) containing 2 treatment periods, with at least a 7-day washout between each dose.

The study will consist of a screening period between 21 and 2 days before the first study treatment administration on Period (P) 1 Day (D) 1, 2 treatment periods of 5 days each, and a washout of at least 7 days between P1D1 and P2D1.

Study treatments are given by the oral route in fasted condition. The end-of-study (EOS) visit will be performed 30 (± 3) days after the last study treatment administration or discontinuation.

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Phase 1

Contacts and Locations

Study Locations

• France
  • Rennes, France, 35000
    • Biotrial

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy participant.
2. Female participants must be postmenopausal or sterilized.
3. Body mass index (BMI) of ≥ 18.5 to < 30 kg/m2, with body weight ≥ 50 kg and < 100 kg.
4. Vital signs within the following ranges or if out of normal ranges, considered as not clinically significant by the Investigator.
5. Participants must have safety laboratory values within the normal ranges or if out of normal ranges considered as not clinically significant by the Investigator.

Exclusion Criteria:

1. Pregnant or currently breastfeeding women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
2. A past medical history of clinically significant ECG abnormalities or a family history (grandparents, parents, and siblings) of prolonged QT interval syndrome.
3. Impaired cardiovascular function.
4. History of fainting spells or orthostatic hypotension episodes.
5. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the participant in case of participation in the study.
6. History of autonomic dysfunction or Gilbert syndrome.
7. History or current evidence of Central serous retinopathy (CSR), Retinal vein occlusion (RVO) or ophthalmopathy as assessed by ophthalmologic examination at baseline that would be considered a risk factor for CSR/RVO [e.g., optic disc cupping, visual field defects, intraocular pressure (IOP) > 21 mmHg].
8. Neuromuscular disorders that were associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
9. Smoker or use of tobacco products or products containing nicotine in the last 4 weeks prior to first dosing of study treatment.

10. Malignancy with the following exceptions:

    1. Adequately treated basal cell or squamous cell carcinoma of the skin (adequate wound healing is required prior to study entry).
    2. Primary malignancy which had been completely resected and was in complete remission for ≥ 5 years.
11. History of retinal degenerative disease.
12. Any vaccination within 4 weeks prior to dosing.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Binimetinib 15 mg / Binimetinib 45 mg; 2 periods	Drug: Binimetinib Oral Tablet; two-period, crossover study
Experimental: Binimetinib 45 mg / Binimetinib 15 mg; 2 periods	Drug: Binimetinib Oral Tablet; two-period, crossover study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Area under the plasma concentration-time curve (AUC) from time of administration to last observed plasma concentration (AUClast)	Through study completion, an average of 2 months
AUC from time of administration to infinity (AUCinf)	Through study completion, an average of 2 months
Maximum observed plasma concentration (Cmax)	Through study completion, an average of 2 months
Time to reach Cmax (Tmax)	Through study completion, an average of 2 months
AUC Test(T) / Reference (R) ratios	Through study completion, an average of 2 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-emergent adverse events (TEAEs)	Incidence, nature and severity	Through study completion, an average of 2 months
Treatment-emergent serious adverse events (treatment-emergent SAEs)	Incidence, nature and severity	Through study completion, an average of 2 months
Electrocardiograms	heart rate (HR), PR interval, QRS duration, QRS axis, QT interval, QTcF	Through study completion, an average of 2 months
Clinical laboratory parameters	Erythrocytes (red blood cells, RBCs), hematocrit, hemoglobin, platelets; leukocyte count with differential: basophils, eosinophils, lymphocytes, monocytes, neutrophils / absolute neutrophil count; RBC indices: mean corpuscular hemoglobin, mean corpuscular volume, reticulocytes/erythrocytes, ALT, albumin, ALP, AST, bicarbonate, bilirubin (total and indirect), urea, calcium, chloride, CK, creatinine, amylase, lipase, total cholesterol, glucose, lactate dehydrogenase, magnesium, potassium, sodium, total protein, uric acid, blood pregnancy test (hCG), coagulation (aPTT or PT)	Through study completion, an average of 2 months
Vital signs	Supine and standing systolic BP, diastolic BP and PR, body temperature	Through study completion, an average of 2 months
Opthalmologic examinations	Best corrected visual acuity for distance testing, optical coherence tomography and/or fluorescein angiography, slit lamp examination, IOP and dilated fundoscopy with attention to retinal abnormalities	At the screening and at the end of study

Collaborators and Investigators

• Sponsor: Pierre Fabre Medicament
• Collaborators: Biotrial
• Investigators: Principal Investigator: Marina Klein, MD, Biotrial

Study record dates

Study Major Dates

• Study Start (Actual): September 3, 2021
• Primary Completion (Anticipated): November 29, 2021
• Study Completion (Anticipated): November 29, 2021

Study Registration Dates

• First Submitted: September 29, 2021
• First Submitted That Met QC Criteria: October 22, 2021
• First Posted (Actual): November 2, 2021

Study Record Updates

• Last Update Posted (Actual): December 1, 2021
• Last Update Submitted That Met QC Criteria: November 30, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Melanoma
• Other Study ID Numbers: W00074CI101_1PF73

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No